Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex.

Abstract excerpt

BACKGROUND: The anti-interleukin 17A agent secukinumab has been approved for the treatment of spondyloarthritis (SpA) patients as an alternative to tumor necrosis factor inhibitors (TNFis). Our aim was to compare long-term treatment persistence and relevant effect modifiers, as well as 6-month clinical responses, in SpA patients starting secukinumab versus TNFis in routine clinical care. METHODS: This was a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Monoclonal, Humanized
• Share to Antirheumatic Agents